Equity Overview
Price & Market Data
Price: $6.46
Daily Change: +$0.32 / 4.95%
Range: $6.09 - $6.53
Market Cap: $286,654,112
Volume: 132,212
Performance Metrics
1 Week: 8.51%
1 Month: 6.56%
3 Months: -64.64%
6 Months: -73.55%
1 Year: -73.55%
YTD: -71.62%
Company Details
Employees: 75
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. The company also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.